<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>N4-Palmitoyl-1-beta-D-arabinofuranosylcytosine (PLAC) was administered PO to 76 patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs), and <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Of 20 patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>, 2 achieved complete remission, and the only patient with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> achieved partial remission </plain></SENT>
<SENT sid="2" pm="."><plain>Remission was reached with PLAC 100-300 mg/day 25-66 days after the start of therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Among 22 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 1 patient achieved a good response and 8 achieved partial response </plain></SENT>
<SENT sid="4" pm="."><plain>Responses were reached with PLAC 50-200 mg/day 7-153 days (median, 33 days) after the start of therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Improvement of <z:hpo ids='HP_0001901'>polycythemia</z:hpo> was observed in <z:hpo ids='HP_0000001'>all</z:hpo> 5 patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, and reduction of <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> was observed in 5 out of 6 patients with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>An antileukemia effect was noted in 1 of 5 with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Major side effects were gastrointestinal toxicities and <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In spite of the disadvantages, such as unpredictable absorption and a lower response rate to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> compared with its parent compound, this antileukemia Ara-C analogue that is administrable PO will be useful in the treatment of MDSs and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e>, which do not necessarily require admission to hospital, and in the treatment of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> of the aged, a condition for which intensive chemotherapy is not appropriate </plain></SENT>
</text></document>